OCUL
Ocular Therapeutix Inc
7.50$
+3.9%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 87.0% | 92.1% | 96.5% | 96.4% | 96.5% | 96.3% | 95.5% | 96.0% | 94.2% | 96.8% | 96.4% | 96.0% | |
| 68.1% | 77.7% | 89.6% | 88.9% | 87.1% | 85.6% | 86.1% | 86.7% | 83.9% | 91.2% | 91.0% | 89.2% | |
| 68.1% | 77.7% | 89.6% | 88.9% | 87.1% | 85.6% | 86.1% | 86.7% | 83.9% | 91.2% | 91.0% | 89.2% | |
| 14.5% | 10.4% | 4.9% | 5.8% | 6.2% | 7.1% | 6.2% | 6.7% | 7.5% | 3.8% | 3.3% | 4.5% | |
| 1.4% | 0.9% | 0.5% | 0.5% | 0.5% | 0.7% | 0.8% | 0.7% | 0.8% | 0.4% | 0.5% | 0.6% | |
| 95.2% | 63.8% | 24.3% | 27.0% | 28.2% | 31.1% | 34.5% | 32.2% | 37.2% | 19.0% | 20.6% | 22.5% | |
| 21.6% | 13.8% | 4.5% | 5.8% | 7.4% | 9.0% | 9.3% | 9.5% | 12.0% | 6.3% | 6.5% | 7.3% | |
| 1.2% | 0.6% | 0.3% | 0.3% | 0.4% | 0.4% | 0.5% | 0.6% | 0.7% | 0.3% | 0.4% | 0.5% | |
| 2.5% | 1.7% | 1.2% | 0.7% | 0.8% | 0.9% | 1.1% | 1.3% | 1.5% | 0.5% | 1.1% | 1.0% | |
| 45.5% | 29.7% | 12.3% | 13.0% | 13.8% | 15.0% | 17.0% | 15.5% | 17.2% | 8.8% | 9.8% | 10.8% | |
| 4.8% | 36.2% | 75.7% | 73.0% | 71.8% | 68.9% | 65.5% | 67.8% | 62.8% | 81.0% | 79.4% | 77.5% | |
| -411.6% | -276.8% | -141.5% | -155.9% | -171.8% | -194.6% | -235.3% | -226.7% | -265.9% | -143.2% | -170.0% | -197.3% | |
| 52.4% | 43.2% | 24.5% | 32.1% | 34.1% | 36.7% | 41.7% | 38.2% | 44.8% | 27.6% | 30.6% | 33.5% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.